Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $24.05. The company's market cap stands at 136.71B, with a P/E ratio of 14.24 and a dividend yield of 7.0%.
On 2025-11-10, Pfizer(PFE) stock moved within a range of $23.93 to $24.89. With shares now at $24.05, the stock is trading +0.5% above its intraday low and -3.4% below the session's peak.
Trading activity shows a volume of 57.28M, compared to an average daily volume of 109.69M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Metsera (MTSR) stock toppled Monday after the buyout battle with Pfizer (PFE) and Novo Nordisk (NVO) ended. Pfizer will acquire the small obesity-focused biotec...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late...
Danish drug giant Novo Nordisk’s shares rose modestly during early trading on Monday. This came after reports that Novo Nordisk’s pursuit of obesity market deal...
Analyst ratings
58%
of 24 ratingsMore PFE News
J.P. Morgan analyst Chris Schott has maintained their neutral stance on PFE stock, giving a Hold rating on November 6. Meet Your ETF AI Analyst Discover how Tip...
Pfizer (PFE) has reached a deal to buy Metsera (MTSR), a weight-loss drug startup, in a transaction that could total more than $10 billion. The agreement follow...
Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc....
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Meet Your ETF AI Analyst Discover how TipRanks' ETF...
Metsera (MTSR) announced that it has entered into an amended merger agreement with Pfizer (PFE), pursuant to which Pfizer will acquire Metsera for up to $86.25...
Healthcare M&A Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal Nov. 08, 2025 6:42 AM ET Pfizer Inc. (PFE) Stock, NVO Stock, MTSR Stock, NONOF...
Pfizer Inc. (NYSE:PFE) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. (NASDAQ:MTSR), beating out Novo Nordisk A/S (NYSE:NVO) after a...
